BioSpace News Archive

ITUS Corporation today announced that on October 1, 2018, the Company will officially change its name to Anixa Biosciences, Inc.

CASI Pharmaceuticals, Inc. announces the appointment of George Chi to the position of Chief Financial Officer.

JLK Inspection, Inc. will participate in the 104th Radiological Society of North America (RSNA) 2018 in Chicago, USA, from November 25th to 30th to display the latest AI-based medical image diagnosis supporting system.

Focuses on digital health initiatives intended to improve health outcomes and drive increased efficiency

ProtoKinetix Inc. (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) Is pleased to announce the launch of a proof of concept study in the field of cardiovascular sciences.

MTF Biologics is expanding its portfolio of innovations for post-mastectomy breast reconstruction with the launch of an acellular dermal matrix (ADM) designed specifically for pre-pectoral breast reconstruction procedures: FlexHD Pliable PRE.

Agreement creates academic health system focused on patient-centered care, innovation and clinical excellence

Eisai Inc.. announced today that the Food and Drug Administration (FDA) expanded the indication of its antiepileptic drug FYCOMPA® (perampanel) CIII for monotherapy and adjunctive use in pediatric patients 4 years and older for the treatment of partial-onset seizures (POS) with or without secondarily generalized seizures.

Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of Aceto Corporation (“Aceto” or the “Company”) (NASDAQ: ACET) resulting from allegations that Aceto and/or its executives may have issued materially misleading business information to the investing public.

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today announced the launch of a new non-interventional patient registry, called Tracing the Effect of the MC4R Pathway in Obesity (TEMPO).